AR082692A1 - Terapia de combinacion para el tratamiento del cancer, producto farmaceutico, equipo, kit - Google Patents
Terapia de combinacion para el tratamiento del cancer, producto farmaceutico, equipo, kitInfo
- Publication number
- AR082692A1 AR082692A1 ARP110102962A ARP110102962A AR082692A1 AR 082692 A1 AR082692 A1 AR 082692A1 AR P110102962 A ARP110102962 A AR P110102962A AR P110102962 A ARP110102962 A AR P110102962A AR 082692 A1 AR082692 A1 AR 082692A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical product
- cancer
- phenyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Terapia de combinación para tratar a un paciente que sufre de un trastorno proliferativo, de una forma particular, un tumor sólido, por ejemplo, un melanoma, un cáncer de tiroides y un cáncer colorrectal.Reivindicación 1: Un producto farmacéutico, el cual comprende, como un agente activo, (A) la {3-[5-(4-cloro-fenil)-1H-pirrolo[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico, o una sal de ésta, farmacéuticamente aceptable; y (B), un segundo componente, el cual comprende, como un ingrediente activo, un inhibidor de topoisomerasa; como una preparación combinada para el uso simultáneo o secuencial, en el tratamiento de un trastorno proliferativo, de una forma particular, un cáncer, de una forma más particular, un cáncer colorrectal, un melanoma y un cáncer de tiroides, que comprende una b-Raf que tiene una mutación V600. Reivindicación 3: El producto farmacéutico, según la reivindicación 1 ó 2, en donde, el citado inhibidor de topoisomerasa, es el irinotecan, o una sal de éste, farmacéuticamente aceptable. Reivindicación 5: El producto farmacéutico, según la reivindicación 4, en donde, el citado inhibidor de EGFR, es el cetuximab. Reivindicación 7: El producto farmacéutico, según una cualquiera de las reivindicaciones 1 a 6, que comprende {3-[5-(4-clorofenil)-1H-pirrolo[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico, o una sal de ésta, farmacéuticamente aceptable, contenida en un complejo molecular sólido, formado con acetato-succinato de hidroxipropilmetilcelulosa, de tal forma que, ésta, se encentra inmovilizada en su estado amorfo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37428810P | 2010-08-17 | 2010-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082692A1 true AR082692A1 (es) | 2012-12-26 |
Family
ID=44651664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102962A AR082692A1 (es) | 2010-08-17 | 2011-08-15 | Terapia de combinacion para el tratamiento del cancer, producto farmaceutico, equipo, kit |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120045433A1 (es) |
| EP (1) | EP2605766A2 (es) |
| JP (1) | JP2013538200A (es) |
| KR (1) | KR20130073948A (es) |
| CN (1) | CN103491952A (es) |
| AR (1) | AR082692A1 (es) |
| AU (1) | AU2011290857A1 (es) |
| CA (1) | CA2807218A1 (es) |
| MX (1) | MX2013001531A (es) |
| SG (1) | SG187828A1 (es) |
| TW (1) | TW201213326A (es) |
| WO (1) | WO2012022677A2 (es) |
| ZA (1) | ZA201300762B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US9295669B2 (en) * | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| SI2882440T1 (sl) | 2012-08-07 | 2019-05-31 | Novartis Ag | Farmacevtske kombinacije, ki vsebujejo inhibitor B-RAF, inhibitor EGFR in neobvezno inhibitor PI3K-alfa |
| CA2879252C (en) | 2012-08-17 | 2017-10-10 | F. Hoffmann-La Roche Ag | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| CN116333154A (zh) * | 2019-08-19 | 2023-06-27 | 美勒斯公司 | 用结合lgr5和egfr的抗体与拓扑异构酶i抑制剂的组合治疗癌症 |
| KR20230127007A (ko) * | 2022-02-24 | 2023-08-31 | 한국생명공학연구원 | Ednra 억제제를 유효성분으로 포함하는 대장암의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1251850B1 (en) * | 2000-01-26 | 2006-06-21 | Schering Corporation | Use of a combination preparation in cancer therapy |
| US6545010B2 (en) * | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| AU2001261473B2 (en) * | 2000-05-15 | 2006-09-14 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for the treatment of colorectal cancer |
| MXPA03003161A (es) * | 2000-10-13 | 2004-05-05 | Vion Pharmaceuticals Inc | Formas de profarmaco modificadas de ap/amp. |
| GB0123400D0 (en) * | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US20080193445A1 (en) * | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
| US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
| TW200533339A (en) * | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
| CA2604300A1 (en) * | 2005-04-14 | 2006-10-19 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-egfr antibody therapy based on an increased copy number of the egfr gene in tumor tissues |
| EP1917019A2 (en) * | 2005-05-03 | 2008-05-07 | Biopolymer Engineering, Inc. | Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection |
| US20060257400A1 (en) * | 2005-05-13 | 2006-11-16 | Bristol-Myers Squibb Company | Combination therapy |
| RS52010B (en) * | 2005-06-22 | 2012-04-30 | Plexxikon Inc. | DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE |
| EP2015775B1 (en) * | 2006-05-03 | 2011-06-01 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
| EP2074226A2 (en) * | 2006-09-19 | 2009-07-01 | Novartis AG | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| EP2133095A4 (en) * | 2007-03-05 | 2012-09-26 | Kyowa Hakko Kirin Co Ltd | PHARMACEUTICAL COMPOSITION |
| CN102864151B (zh) * | 2007-08-01 | 2015-07-08 | 艾德拉药物股份有限公司 | Tlr9的新型合成性激动剂 |
-
2011
- 2011-08-10 US US13/206,548 patent/US20120045433A1/en not_active Abandoned
- 2011-08-12 WO PCT/EP2011/063892 patent/WO2012022677A2/en active Application Filing
- 2011-08-12 CA CA2807218A patent/CA2807218A1/en not_active Withdrawn
- 2011-08-12 AU AU2011290857A patent/AU2011290857A1/en not_active Withdrawn
- 2011-08-12 KR KR1020137006538A patent/KR20130073948A/ko not_active Application Discontinuation
- 2011-08-12 JP JP2013524420A patent/JP2013538200A/ja not_active Withdrawn
- 2011-08-12 EP EP11757192.7A patent/EP2605766A2/en not_active Withdrawn
- 2011-08-12 SG SG2013010657A patent/SG187828A1/en unknown
- 2011-08-12 CN CN201180050099.0A patent/CN103491952A/zh not_active Withdrawn
- 2011-08-12 MX MX2013001531A patent/MX2013001531A/es not_active Application Discontinuation
- 2011-08-15 TW TW100129118A patent/TW201213326A/zh unknown
- 2011-08-15 AR ARP110102962A patent/AR082692A1/es unknown
-
2013
- 2013-01-29 ZA ZA2013/00762A patent/ZA201300762B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012022677A3 (en) | 2013-07-25 |
| CA2807218A1 (en) | 2012-02-23 |
| CN103491952A (zh) | 2014-01-01 |
| SG187828A1 (en) | 2013-03-28 |
| EP2605766A2 (en) | 2013-06-26 |
| TW201213326A (en) | 2012-04-01 |
| ZA201300762B (en) | 2014-07-30 |
| MX2013001531A (es) | 2013-03-18 |
| JP2013538200A (ja) | 2013-10-10 |
| US20120045433A1 (en) | 2012-02-23 |
| WO2012022677A2 (en) | 2012-02-23 |
| KR20130073948A (ko) | 2013-07-03 |
| AU2011290857A1 (en) | 2013-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082692A1 (es) | Terapia de combinacion para el tratamiento del cancer, producto farmaceutico, equipo, kit | |
| AR082691A1 (es) | Terapia de combinacion, producto farmaceutico, kit y uso | |
| MX2019013643A (es) | Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona. | |
| EP4353747A3 (en) | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer | |
| WO2013059737A3 (en) | Tissue treatment device and related methods | |
| BR112014018910A8 (pt) | Produto farmacêutico , kit, uso de vemurafenibe, produtos, métodos, composições e usos inovadores | |
| WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
| WO2009126931A3 (en) | Therapy for bipolar disorder and mania with buprenorphine | |
| EA201590870A1 (ru) | АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ | |
| PH12015502337A1 (en) | Ibrutinib combination therapy | |
| MX346455B (es) | Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica. | |
| WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| WO2009109927A3 (en) | Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer | |
| WO2009143156A3 (en) | Imidazo [1, 2-a] pyridine compounds as gaba-a receptor modulators | |
| CL2013002005A1 (es) | Compuesto 8-[5-(1-hidroxi-1-metiletil)piridin-3-il]-1-[(2s)-2-metoxipropil]-3-metil-1,3-dihidro-2h-imidazo[4,5-c]quinazolin-2-ona; inhibidor pi3k y como mtor; composicion farmaceutica que lo comprende; combinacion farmceutica; y su uso en el tratamiento del cancer. | |
| BR112013011480A8 (pt) | método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer | |
| EA201170940A1 (ru) | Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела | |
| WO2016207090A3 (en) | Targeted conjugates of ksp inhibitors | |
| AR084233A1 (es) | Terapia de combinacion que comprende {3-[5-(4-clorofenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-di-fluor-fenil}-amida del acido propano-1-sulfonico y un interferon para el uso en el tratamiento del cancer y kit | |
| GB201111485D0 (en) | Drug composition and its use in therapy | |
| GT201300235A (es) | Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas | |
| WO2013071056A3 (en) | Combination drug therapy for the treatment of solid tumors | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| UA103792C2 (uk) | Похідна бензодіазепіну для лікування гемопоетичної неоплазми та лейкозу | |
| CL2011000116A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |